QUEENSBURY, N.Y. Delcath Systems, Inc. (Nasdaq: DCTH), an innovative interventional oncology company specializing in the treatment of both primary and metastatic cancers of the liver, has proudly announced its participation in two prominent upcoming investor conferences. This strategic involvement underscores Delcath’s ongoing commitment to advancing its clinical goals and engaging with the investment community to foster widespread understanding and support for its pioneering therapies.
BTIG Virtual Biotechnology Conference
- ’Date:’ Tuesday, August 6, 2024
- ’Location:’ Virtual
Delcath Systems will debut its plans and progress at the BTIG Virtual Biotechnology Conference on August 6, 2024. The virtual nature of this conference allows Delcath to reach a global audience, providing crucial updates to investors and stakeholders from diverse geographical locations. The emphasis on biotechnology within the forum resonates with Delcath’s commitment to cutting-edge oncological solutions and its pursuit of innovative liver cancer treatments.
Canaccord Genuity’s 44th Annual Growth Conference
- ’Date:’ Wednesday, August 14, 2024
- ’Presentation Time:’ 9:30 AM Eastern Time
- ’Location:’ Boston, MA
Further showcasing its advancements, Delcath will present at Canaccord Genuity’s 44th Annual Growth Conference. Scheduled for August 14, 2024, at 9:30 AM Eastern Time in Boston, MA, this event will feature Delcath’s management team, who will delve into the company’s latest achievements and future prospects. This prestigious growth conference promises to offer a dynamic platform for Delcath to highlight its state-of-the-art liver cancer therapies to an influential audience of investors and industry experts.
A Strategic Opportunity
Participation in these significant investor conferences demonstrates Delcath’s proactive approach to investor relations and its steadfast dedication to communicating its clinical s and innovative treatment methodologies to an informed and engaged audience. By engaging with the investment community through these esteemed forums, Delcath aims to attract critical support and investment that will drive the progress of its life-enhancing therapies for liver cancer patients globally.
About Delcath Systems, Inc.
Delcath Systems, Inc. is at the forefront of interventional oncology, specializing in the treatment of primary and metastatic liver cancers through minimally invasive, tumor-targeted therapies. The company’s proprietary Melphalan/HDS system is designed to deliver high-dose chemotherapy directly to the liver while minimizing systemic exposure, offering a potentially transformative treatment option for patients with hepatic malignancies.
Moving Forward
As Delcath Systems prepares to participate in the BTIG Virtual Biotechnology Conference and Canaccord Genuity’s 44th Annual Growth Conference, the company remains committed to its mission of advancing cancer care. These conferences represent pivotal opportunities for Delcath to share its innovations and clinical results, furthering its vision to become a leader in liver cancer treatment.
Comments